PREPRINT (not peer reviewed)

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: PsyArXiv
Date: 2022-10-05
Source: PsyArXiv
DOI: 10.31234/osf.io/85s9p
PubMed: Unavailable

Authors

Ching THW Kichuk S DePalmer G Pittenger C Kelmendi B.

Watch author

Derived topics and classifications

psilocybin OCD Safety Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.Frontiers in psychiatry · 2024-01-01 Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCDPsyArXiv · 2023-03-17 Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.Frontiers in psychiatry · 2023-01-01 Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.Frontiers in psychiatry · 2023-01-01 A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.Psychedelic medicine (New Rochelle, N.Y.) · 2025-03-01 Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.Frontiers in psychiatry · 2025-01-01 Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report.Heliyon · 2022-12-01 A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderClinicalTrials.gov · 2026-08-18